利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

344 条记录 (耗时 0.027 秒)

    Cell supporting matrix, cell culture device, and fluid treating device
    43.
    发明公开
    Cell supporting matrix, cell culture device, and fluid treating device 有权
    Zellträgermatrix，VorrichtungfürZellkulturen undFlüssigkeitsbehandlung

    公开(公告)号：EP0967273A1

    公开(公告)日：1999-12-29

    申请号：EP99401562.6

    申请日：1999-06-23

    申请人： TERUMO KABUSHIKI KAISHA

    发明人： Kimura, Tetsuhiro ,  Tokunaga, Norifumi ,  Omura, Yoshitaka

    IPC分类号： C12N15/06

    CPC分类号： C12M25/14 ,  A61K35/12 ,  C12N5/0068 ,  C12N5/0671 ,  C12N2533/30 ,  C12N2533/78

    摘要： A cell supporting matrix which enables the cells to be supported at a high efficiency and at a high density in a short period is provided. The cell supporting matrix comprises a cell supporting layer 7 for supporting the cells, and a skin layer 8. The cell supporting layer 7 has formed therein a plurality of large pores 5 having a larger pore size and a plurality of communicating pores 6 having a smaller pore size. The large pores 5 are in finger-like structure form and are distributed in the cell supporting matrix 4. The longitudinal axis of the large pores 5 extends substantially in the flow direction of the fluid passing through the cell supporting matrix 4. The large pores 5 do not extend through the cell supporting matrix 4. The communicating pores 6 are formed such that their pore size decreases from the surface to the interior of the cell supporting matrix 4. The pore size of the communicating pores 6 range from below to beyond the size of the cells to be supported on the matrix 4.

    摘要翻译： 提供了能够在短时间内以高效率和高密度地支撑电池的电池支撑基体。 电池支撑基体包括用于支撑电池的电池支撑层7和表皮层8.电池支撑层7中形成有多个具有较大孔径的大孔5和多个具有较小孔径的连通孔6 孔径。 大孔5处于指状结构形式并分布在细胞支撑基体4中。大孔5的纵向轴线基本上沿流过细胞支撑基质4的流体的流动方向延伸。大孔5 不延伸通过电池支撑基体4.连通孔6形成为使得它们的孔径从电池支撑基体4的表面到内部减小。连通孔6的孔径从下到下超过尺寸 要支撑在矩阵4上的单元格。

    ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE SAME, AND USE THEROF
    47.
    发明公开
    ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE SAME, AND USE THEROF 失效
    MONOKLONALERANTIKÖRPERGEGEN ANTIANNEXIN-V，VERFAHREN ZU SEINER HERSTELLUNG UND SEINER VERWENDUNG

    公开(公告)号：EP0741144A1

    公开(公告)日：1996-11-06

    申请号：EP95936774.9

    申请日：1995-11-10

    申请人： INTERNATIONAL REAGENTS CORPORATION ,  KANEKO, Noboru

    发明人： KANEKO, Noboru ,  MATSUDA, Ryuko ,  KAJITA,Tadahiro International Reagents Corporation ,  OHTA, Yohsuke International Reagents Corporation

    IPC分类号： C07K16/18 ,  C12P21/08 ,  C12N15/06 ,  C12N5/20 ,  G01N33/577

    CPC分类号： C07K16/18 ,  G01N2333/4718

    摘要： Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris. There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.

    摘要翻译： 使用人膜联蛋白-V或人膜联蛋白-V加狗膜联蛋白-V作为抗原，制备能够产生对膜联蛋白-V上的抗原决定簇位点具有结合特异性的抗膜联蛋白-V单克隆抗体的杂交瘤细胞系 作为抗原蛋白，属于免疫球蛋白G类。 通过杂交瘤细胞系产生抗膜联蛋白-V单克隆抗体，通过该单克隆抗体提供诊断剂用于诊断心肌梗死和心绞痛。 还提供使用由杂交瘤细胞系产生的第一和第二单克隆抗体来定量样品中的人膜联蛋白-V的心肌梗塞和心绞痛的诊断，其中样品中膜联蛋白-V上的抗原 - 抗体反应为 由第一抗 - 膜联蛋白-V单克隆抗体引起膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物，形成的膜联蛋白-V抗原/膜联蛋白-V单克隆抗体复合物的膜联蛋白-V的抗原位点是 允许与标记的抗膜联蛋白-V多克隆或第二单克隆抗体结合，以形成与多克隆或第二单克隆抗体结合的所述膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的标记形式，以及 对复合物的标记形式进行定量分析。